India’s leading pharmaceutical major Natco Pharma Ltd said on Monday that the company received approval from the Central Drugs Standard Control Organization (CDSCO) of India for emergency use for bacintib tablets for the treatment of coronovirus-positive patients.
In its regulatory filing, the company officially stated: “Netco Pharma Ltd. has received emergency use approval from Central Drugs Standard Control Organization (CDSCO) in India for strength of barcintib tablets, 1mg, 2mg and 4mg. ”
Natco will request a compulsory license based on emergency use and severe light and severe public health emergencies due to the epidemic. The company is set to launch the product this week to make the product available to afflicted patients across India.
The response to the growth of the shares of Natco Pharma Ltd. during the mid-nun session, at NSE at Rs.27 per share was Rs. 30.70 from the previous close of Rs. Is 896.35. In comparison, the NSE Nifty 14,555, a decline of 76 points in trade.